Phillip Scheinberg, M.D.

Dr. Phillip Scheinberg is a staff clinician at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, MD. He is currently involved in clinical protocols in bone marrow failure bone marrow failure: A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be… syndromes such as aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is low. Most… , myelodysplastic syndromes and large granular lymphocytic leukemia. The focus of these protocols is to investigate novel immunosuppressive regimens that will improve the response rate in untreated severe aplastic anemia (SAA) and prevent relapses and clonal evolution to myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at… . In patients with SAA who are not responsive to initial anti-thymocyte globulin (ATG) and cyclosporine cyclosporine: Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and some other forms of bone marrow failure. , protocols are being developed to improve the success of salvage therapies with repeat immunosuppressive therapy immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response. This prevents your immune system from attacking your bone marrow, allowing bone marrow stem cells to grow, which raises blood counts. For older patients with acquired aplastic anemia, immunosuppressive drug therapy is the… . Dr. Scheinberg received an MD Degree in 1995 in Sao Paulo, Brazil, completed an internship and residency (1997-2001) at Mount Sinai Medical Center in Miami Beach, FL and a Hematology/Oncology Fellowship (2001-2005) at the Hematology Branch of NHLBI